| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | A-S Medication Solutions | 20260603 | 8 |
| NALOXONE HYDROCHLORIDE | Hospira, Inc. | 20260527 | 35 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | REMEDYREPACK INC. | 20260522 | 8 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS . BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260514 | 107 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260514 | 106 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260513 | 6 |
| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | Somerset Therapeutics, LLC | Somerset Therapeutics Private Limited | 20260505 | 10 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Rhodes Pharmaceuticals LLC | Knoa Pharmaceuticals LLC | Halo Pharmaceutical Inc. | 20260501 | 9 |
| BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Golden State Medical Supply, Inc. | 20260424 | 2 |
| NARCAN® Naloxone HCl Nasal Spray 4 mg Drug Facts | Sportpharm LLC | 20260424 | 2 |
| NARCAN® Naloxone HCl Nasal Spray 4 mg Drug Facts | Emergent Devices Inc. | 20260422 | 2 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002 | Redpharm Drug | 20260422 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS . BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Unit Dose Solutions, Inc. | 20260416 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260416 | 2 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002 | Aveva Drug Delivery Systems Inc. | DifGen Pharmaceuticals LLC | 20260407 | 2 |
| These highlights do not include all the information needed to use B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260403 | 1007 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260403 | 104 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20260403 | 102 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002 | INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems, Inc | 20260323 | 6 |
| 4d66b96a-acbb-2292-e063-6294a90af788 | HF Acquisition Co. LLC. DBA HealthFirst | 20260319 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Clinical Solutions Wholesale, LLC | 20260306 | 2 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Clinical Solutions Wholesale, LLC | 20260305 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Major Pharmaceuticals | 20260303 | 9 |
| These highlights do not include all the information needed to use REZENOPY nasal spray safely and effectively. See full prescribing information for REZENOPY nasal spray. REZENOPY™ (naloxone HCl) nasal spray, 10 mg Initial U.S. Approval:1971 | Scienture LLC | Summit Biosciences Inc. | 20260303 | 7 |
| NALOXONE HYDROCHLORIDE INJECTION, USP Opioid Antagonist Rx Only | Henry Schein, Inc | 20260302 | 10 |
| These highlights do not include all the information needed to use BUBRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 | Redpharm Drug | 20260221 | 4 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE Sublingual Tablets for sublingual administration CIII Initial U.S. Approval: 2002 | PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma | Ethypharm USA Corp. | 20260219 | 7 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Unit Dose Solutions, Inc. | 20260219 | 1 |
| 68df290c-d776-4cfc-9565-332eb56c4723 | REMEDYREPACK INC. | 20260210 | 8 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Sun Pharmaceutical Industries, Inc. | Sun Pharmaceutical Industries Limited | 20260210 | 33 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx only | Lifestar Pharma LLC | Mankind Pharma Limited | 20260209 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE s ublingual t ablets, CIII Initial U.S. Approval: 2002 | Actavis Pharma, Inc. | 20260206 | 49 |
| These highlights do not include all the information needed to use B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Amneal Pharmaceuticals LLC | 20260202 | 55 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002 | Camber Pharmaceuticals, Inc. | Ascent Pharmaceuticals, Inc. | 20260130 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Lannett Company, Inc. | 20260128 | 32 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Camber Pharmaceuticals, Inc. | Ascent Pharmaceuticals, Inc. | 20260128 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Redpharm Drug | 20260123 | 2 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | Hikma Pharmaceuticals USA Inc. | West-Ward Columbus Inc. | 20260123 | 31 |
| These highlights do not include all the information needed to use BUBRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 | Mylan Pharmaceuticals Inc. | 20260115 | 12 |
| Naloxone Hydrochloride Nasal Spray | AvKARE | 20260114 | 2 |
| RiVive ® Naloxone HCl Nasal Spray 3 mg Emergency Treatment of Opioid Overdose | Harm Reduction Therapeutics, Inc. | 20260113 | 2 |
| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | Sina Health Inc | 20260112 | 11 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 | Dr.Reddys Laboratories Inc | LTS Lohmann Therapy Systems Corp. | Pharmaron Manufacturing services (UK) LTD | 20260112 | 10 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 | Dr.Reddys Laboratories Inc | LTS Lohmann Therapy Systems Corp. | Pharmaron Manufacturing services (UK) LTD | 20260112 | 11 |
| Buprenorphine and Naloxone Sublingual Tablets CIII Rx Only These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | AvPAK | 20260108 | 11 |
| Naloxone HCl Nasal Spray Drug Facts | Padagis Israel Pharmaceuticals Ltd | 20260106 | 5 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002 | Alvogen Inc. | 20260101 | 19 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII. Initial U.S. Approval: 2002 | Redpharm Drug | 20251227 | 4 |
| These highlights do not include all the information needed to use NALOXONE HYDROCHLORIDE NASAL SPRAY safely and effectively. See full prescribing information for NALOXONE HYDROCHLORIDE NASAL SPRAY. NALOXONE HYDROCHLORIDE nasal spray Initial U.S. Approval: 1971 | Redpharm Drug | 20251227 | 3 |
| These highlights do not include all the information needed to use ZUBSOLV ® safely and effectively. See full prescribing information for ZUBSOLV. ZUBSOLV (buprenorphine and naloxone sublingual tablets), CIII Initial U.S. Approval: 2002 | Orexo US, Inc. | 20251227 | 27 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx only | BPI Labs LLC | 20251226 | 4 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS . BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | SpecGx LLC | 20251224 | 33 |
| These highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual film. SUBOXONE ® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002 | INDIVIOR INC. | Alcami Carolinas Corporation | Aquestive Therapeutics | Butterworth Laboratories Ltd | INDIVIOR UK Limited | Infinity Labs IN, Inc | Macfarlan Smith Limited | PPD Development, L.P. | QUOTIENT SCIENCES (ALNWICK) LIMITED | SGS North America Inc. | Sharp Packaging Services, LLC | Siegfried AG | SpecGx LLC | Veranova, L.P. | 20251222 | 37 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Redpharm Drug | 20251211 | 3 |
| Naloxone Hydrochloride Nasal Spray | Amneal Pharmaceuticals NY LLC | 20251209 | 11 |
| These highlights do not include all the information needed to use NARCAN ® NASAL SPRAY safely and effectively. See full prescribing information for NARCAN ® NASAL SPRAY. NARCAN ® (naloxone hydrochloride) nasal spray Initial U.S. Approval: 1971 | Emergent Devices Inc. | 20251205 | 24 |
| ZIMHI ® (naloxone hydrochloride injection, USP) These highlights do not include all the information needed to use ZIMHI ® safely and effectively. See full prescribing information for ZIMHI ® . ZIMHI ® (naloxone hydrochloride injection, USP) prefilled syringe for intramuscular or subcutaneous use 5 mg/0.5 mL. Initial U.S. Approval: 1971 | ZMI Pharma Inc. | 20251204 | 3 |
| Naloxone HCl Nasal Spray Drug Facts | Strategic Sourcing Services LLC | 20251119 | 2 |
| Pentazocine and Naloxone Tablets , USP CIV | Actavis Pharma, Inc. | 20251031 | 28 |
| Naloxone Hydrochloride | Henry Schein, Inc. | 20251028 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | REMEDYREPACK INC. | 20251027 | 3 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20251023 | 100 |
| Naloxone HCl Nasal Spray Drug Facts | BluePoint Laboratories | Padagis Israel Pharmaceuticals Ltd | 20251008 | 2 |
| These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002 | REMEDYREPACK INC. | 20250924 | 7 |
| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | ProPharma Distribution | 20250919 | 1 |
| Naloxone HCL | Henry Schein, Inc. | 20250905 | 5 |
| Naloxone Hydrochloride Injection, USP | Hikma Pharmaceuticals USA Inc. | 20250902 | 7 |
| Naloxone HCl Nasal Spray Drug Facts | AMERISOURCE BERGEN | 20250831 | 2 |
| Pentazocine and Naloxone Tablets, USP CIV Revised: August 2025 Analgesic for Oral Use Only | Lupin Pharmaceuticals,Inc. | Lupin Inc. | Novel Laboratories, Inc. | 20250828 | 16 |
| These highlights do not include all the information needed to use KLOXXADO safely and effectively. See full prescribing information for KLOXXADO. KLOXXADO ® (naloxone hydrochloride) nasal spray Initial U.S. Approval: 1971 | Hikma Specialty USA Inc. | Hikma Pharmaceuticals USA Inc. | West-Ward Columbus Inc. | 20250825 | 5 |
| 3ba53405-5e72-c035-e063-6294a90ac0b1 | HF Acquisition Co LLC, DBA HealthFirst | 20250805 | 1 |
| 201fdedf-1736-4e52-9d7d-de14292547fd | Fresenius Kabi USA, LLC | 20250731 | 5 |
| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | ProPharma Distribution | 20250718 | 3 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx only | Eugia US LLC | EUGIA PHARMA SPECIALITIES LIMITED | 20250514 | 6 |
| Naloxone Hydrochloride Injection | NorthStar RxLLC | Mankind Pharma Limited | 20250127 | 2 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx Only | Henry Schein, Inc. | 20250127 | 5 |
| NALOXONE HYDROCHLORIDE INJECTION, USP 4mg/10mL 0.4mg/mL 10mL VIAL | HF Acquisition Co LLC, DBA HealthFirst | 20250108 | 3 |
| Naloxone Hydrochloride Injection, USP | Civica, Inc. | 20241219 | 4 |
| 236349ef-2cb5-47ca-a3a5-99534c3a4996 | International Medication Systems, Limited | 20241216 | 7 |
| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | Medical Purchasing Solutions, LLC | 20241210 | 1 |
| Drug Facts | Asclemed USA, Inc. | ASCLEMED USA INC. DBA ENOVACHEM | 20241029 | 1 |
| Naloxone Hydrochloride Injection, USP | Baxter Healthcare Corporation | GLAND PHARMA LIMITED | 20241004 | 1 |
| Naloxone HCl Nasal Spray Drug Facts | Bryant Ranch Prepack | 20241003 | 100 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | American Health Packaging | 20240820 | 5 |
| These highlights do not include all the information needed to use NARCAN ® NASAL SPRAY safely and effectively. See full prescribing information for NARCAN ® NASAL SPRAY. NARCAN ® (naloxone hydrochloride) nasal spray Initial U.S. Approval: 1971 | RedPharm Drug | 20240815 | 1 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20240814 | 105 |
| b1303f15-c48b-a44d-b28a-72f370094e02 | Dr. Reddy's Laboratories, Inc. | Dr. Reddy's Laboratories Limited-FTO9 | 20240801 | 8 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 | RedPharm Drug | 20240725 | 1 |
| These highlights do not include all the information needed to use NALOXONE HYDROCHLORIDE NASAL SPRAY safely and effectively. See full prescribing information for NALOXONE HYDROCHLORIDE NASAL SPRAY . NALOXONE HYDROCHLORIDE nasal spray Initial U.S. Approval: 1971 | RedPharm Drug | 20240724 | 1 |
| These highlights do not include all the information needed to use BUBRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 | Redpharm drug | 20240718 | 2 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx only | Eugia US LLC | EUGIA PHARMA SPECIALITIES LIMITED | 20240706 | 4 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx only | Eugia US LLC | EUGIA PHARMA SPECIALITIES LIMITED | 20240706 | 4 |
| Naloxone HCl Nasal Spray | Advanced Rx of Tennessee, LLC | 20240627 | 1 |
| 19b0603b-241f-f439-e063-6294a90ae85f | HF Acquisition Co LLC, DBA HealthFirst | 20240530 | 1 |
| These highlights do not include all the information needed to use B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20240520 | 7 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20240520 | 103 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20240517 | 5 |
| These highlights do not include all the information needed to use REXTOVY™ Nasal Spray safely and effectively. See full prescribing information for REXTOVY™ Nasal Spray. REXTOVY™ (naloxone hydrochloride) Nasal Spray Initial U.S. Approval: 1971 | International Medication Systems, Ltd. | 20240515 | 8 |
| These highlights do not include all the information needed to use REZENOPY nasal spray safely and effectively. See full prescribing information for REZENOPY nasal spray . REZENOPY (naloxone hydrochloride) nasal spray Initial U.S. Approval: 1971 | Summit Biosciences Inc | 20240430 | 1 |
| Naloxone Hydrochloride Nasal Spray | Walgreen Co. | 20240424 | 4 |
| Naloxone Hydrochloride Nasal Spray | CVS Pharmacy, Inc | 20240424 | 5 |
| Naloxone Hydrochloride Nasal Spray | Amneal Pharmaceuticals NY LLC | 20240419 | 5 |
| Naloxone Hydrochloride Injection, USP | Mylan Institutional LLC | 20240412 | 4 |
| Naloxone Hydrochloride Injection, USP | Par Health USA, LLC | 20240411 | 21 |
| Naloxone Hydrochloride Injection, USP | Hikma Pharmaceuticals USA Inc. | 20240410 | 2 |
| Naloxone Hydrochloride Injection, USP Opioid Antagonist Rx only | Lifestar Pharma LLC | Mankind Pharma Limited | 20240304 | 2 |
| NALOXONE HYDROCHLORIDE INJECTION, USP 2mg/2mL (1mg/mL) | HF Acquisition Co LLC, DBA HealthFirst | 20240222 | 3 |
| 11d770b8-b768-ba3d-e063-6394a90a61a6 | HF Acquisition Co LLC, DBA HealthFirst | 20240220 | 1 |
| NALOXONE HYDROCHLORIDE INJECTION, USP 0.4mg/mL 10mL VIAL | HF Acquisition Co LLC, DBA HealthFirst | 20240219 | 3 |
| Drug Facts | Actavis Pharma, Inc. | 20240130 | 1 |
| NALOXONE HYDROCHLORIDE INJECTION, USP 0.4mg PER mL 1mL | HF Acquisition Co LLC, DBA HealthFirst | 20240130 | 3 |
| NALOXONE HCl NASAL SPRAY 4mg/.1mL | HF Acquisition Co LLC, DBA HealthFirst | 20240128 | 2 |
| NALOXONE HCI INJECTION, USP 0.4mg/mL 1mL VIA | HF Acquisition Co. LLC, DBA Health First | HF Acquisition Co. LLC, BDA Health First | 20240127 | 9 |
| NALOXONE HYDROCHLORIDE INJECTION, USP 2mg PER 2mL (1mg/mL) 2mL SYR | HF Acquisition Co LLC, DBA HealthFirst | 20240127 | 2 |
| NALOXONE HYDROCHLORIDE INJ., USP (1mg/mL) 2mL SYR | HF Acquisition Co. LLC, DBA HealthFirst | 20240125 | 6 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002 | Bryant Ranch Prepack | 20240112 | 102 |
| These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002 | Clinical Solutions Wholesale, LLC | 20240109 | 2 |
| Drug Facts | Teva Pharmaceuticals, Inc. | 20240101 | 2 |
| Naloxone HCl Nasal Spray Drug Facts | A-S Medication Solutions | 20231227 | 2 |
| Naloxone Hydrochloride Injection, USP USP type-I clear tubular glass Vial, Opioid Antagonist Protect from light by retaining in the carton until ready for use. Discard unused portion. Rx only | Somerset Therapeutics, LLC | Somerset Therapeutics Limited | 20231219 | 9 |